The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.

Novo Nordisk (NVO) experienced a significant surge in pre-market trading on Friday, with its stock climbing 12% following the announcement of promising results from an early-stage clinical trial for its new obesity treatment,